NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026

Rhea-AI Summary

NRx Pharmaceuticals (Nasdaq: NRXP) will report full year 2025 financial results and provide a corporate update on March 24, 2026. The company will host a conference call at 8:00am ET covering FY2025 results and progress across its drug development programs and the HOPE Therapeutics clinical network.

A live webcast will be available on the company's investor site and telephone dial-ins are provided for domestic and international participants.

News Market Reaction – NRXP

-3.16%

1 alert

-3.16% Session close to close

$58.65M Market Cap

0.0x Rel. Volume

In the Mar 19 session, NRXP declined 3.16%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets expectations for full-year 2025 results and a corporate update on March 24, 2...

Analysis

This announcement sets expectations for full-year 2025 results and a corporate update on March 24, 2026. Recent filings showed a net loss of $28.9 million, a working capital deficit of $28.6 million, and a stockholders’ deficit of $25.8 million, alongside clinical and operational progress. The effective $150,000,000 shelf highlights potential future equity or debt issuance as a key factor to monitor around upcoming disclosures.

Key Figures

Net loss: $28.9 million Accumulated deficit: $307.3 million Total assets: $15.0 million +5 more

8 metrics

Net loss $28.9 million Nine months ended September 30, 2025 (10-Q)

Accumulated deficit $307.3 million As of September 30, 2025 (10-Q)

Total assets $15.0 million As of September 30, 2025 (10-Q)

Total liabilities $40.8 million As of September 30, 2025 (10-Q)

Cash and equivalents $7.2 million As of September 30, 2025 (10-Q)

Working capital deficit $28.6 million As of September 30, 2025 (10-Q)

Shelf registration size $150,000,000 Amended S-3/A shelf filed December 12, 2025

Unsold securities carried $78,644,060 Carried forward under Rule 415(a)(6) in S-3/A

Previous Earnings date Reports

1 past event · Latest: Nov 12 (Positive)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Nov 12	Earnings date set	Positive	+6.0%	Announcement of Q3 2025 results date and related conference call details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior earnings-date announcement saw a positive price reaction, suggesting past anticipation into scheduled results and updates.

Recent Company History

Over recent months, NRx has combined regulatory and clinical progress with financial strain. The 10-Q for the nine months ended September 30, 2025 reported substantial net losses and a going-concern warning while advancing NRX‑100/NRX‑101 and launching clinical operations. An earnings date release on November 12, 2025 for Q3 2025, which set a results call on November 17, 2025, was followed by a 6.02% gain, showing prior market interest in scheduled financial and corporate updates.

Key Terms

at-the-market program, convertible notes, stock options, shelf registration, +2 more

6 terms

at-the-market program financial

"NRx raised capital through two registered direct offerings, an at-the-market program and Anson convertible notes"

An at-the-market program is a way for a company to sell new shares of its stock gradually over time directly into the stock market, rather than all at once. This approach allows the company to raise money as needed while giving investors the opportunity to buy shares at current market prices. It helps manage the timing and price of new stock offerings, providing flexibility for both the company and investors.

convertible notes financial

"NRx raised capital through two registered direct offerings, an at-the-market program and Anson convertible notes"

Convertible notes are a type of short-term loan that a company receives from investors, which can later be turned into company shares instead of being paid back in cash. They matter to investors because they offer a way to support a company early on while giving the potential to own a stake in its success if the company grows and later raises more funding.

stock options financial

"reported a grant of 125,000 stock options on 04/09/2025"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

shelf registration regulatory

"has filed an amended shelf registration to offer up to $150,000,000 of common stock"

Shelf registration is when a company gets permission ahead of time to sell new stocks or bonds over a period of time instead of all at once. It matters to investors because it lets a company raise money quickly when needed, but it can also change the value of existing shares if many new ones are sold.

View in glossary

Abbreviated New Drug Application regulatory

"permits immediate re-filing of the company’s Abbreviated New Drug Application for KETAFREE™"

An abbreviated new drug application is a regulatory submission used to gain approval to market a generic version of an already approved prescription medicine by showing it is equivalent in effect and safety to the original product, without repeating full clinical trials. For investors, an approval signals a lower-cost competitor entering the market that can quickly capture sales from the branded drug, similar to a generic knock‑off replacing a name‑brand item on store shelves.

benzethonium chloride medical

"currently marketed ketamine is supplied in multi-dose vials containing the toxic preservative Benzethonium Chloride"

Benzethonium chloride is a synthetic antimicrobial compound used as a disinfectant, preservative and antibacterial ingredient in personal care, household and medical products. It works like a tiny soap molecule that disrupts and kills germs, which makes it valuable for formulations that need long-lasting protection. Investors watch it because changes in safety reviews, regulations, supply or demand can affect sales, manufacturing costs and the reputations of companies that use it.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WILMINGTON, Del., March 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced that it will host a conference call at 8:00am ET on Tuesday, March 24, 2026.

In addition to reviewing the Company's financial results for the fiscal year ended December 31, 2025, the Company will provide an update on the significant progress achieved across its drug development programs and the HOPE Therapeutics clinical network, milestones that bring the Company closer to its founding mission of preventing suicide and transforming the treatment of depression and PTSD to improve the lives of patients and bring hope to life.

A live webcast of the conference call will be available on the Company’s website at https://ir.nrxpharma.com/events. Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically 1-800-717-1738 or internationally +1-646-307-1865.

About NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA), and initiated a New Drug Application filing for NRX-100 with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal ideation in patients with depression, including bipolar depression.

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information:
Brian Korb
Managing Partner, astr partners
(917) 653-5122
brian.korb@astrpartners.com

FAQ

When will NRx Pharmaceuticals (NRXP) report full year 2025 results and host the conference call?

The conference call is scheduled for March 24, 2026 at 8:00am ET. According to the company, the call will review fiscal year 2025 financial results and provide program updates and clinical network progress.

How can investors access the NRx Pharmaceuticals (NRXP) March 24, 2026 webcast and dial-in details?

Investors can join a live webcast via the company investor events page at ir.nrxpharma.com/events. According to the company, telephone access is available domestically at 1-800-717-1738 and internationally at +1-646-307-1865.

What will NRx Pharmaceuticals (NRXP) discuss about drug development on the March 24, 2026 call?

The company will provide an update on progress across its drug development programs and the HOPE Therapeutics clinical network. According to the company, milestones achieved will be discussed toward advancing treatments for depression, PTSD, and suicide prevention.

Will NRx Pharmaceuticals (NRXP) present fiscal year 2025 financial figures on the March 24, 2026 call?

Yes; the call will review full year 2025 financial results. According to the company, management will discuss FY2025 performance alongside program updates and strategic priorities for 2026.

Is the March 24, 2026 NRx Pharmaceuticals (NRXP) event open to the public and where is the replay available?

The event is open to the public via webcast and phone. According to the company, a live webcast will be available on the investor website and a replay is typically posted after the live event for on-demand access.

What is the primary focus of NRx Pharmaceuticals (NRXP)'s corporate update on March 24, 2026?

The update emphasizes clinical progress and milestones across drug programs and the HOPE Therapeutics network. According to the company, these developments aim to advance treatments for depression, PTSD, and suicide prevention while supporting corporate objectives.